Eli Lilly and Company (NYSE:LLY) develops, manufactures, discovers, and sells pharmaceutical products. These products span ...

Eli Lilly and Company (NYSE:LLY), a leading pharmaceutical giant with a market capitalization of $724 billion, has been ...

Eli Lilly and Company (NYSE:LLY), a leading global pharmaceutical firm, finds itself at a pivotal juncture as it navigates a ...

Eli Lilly LLY2.29%increase; green up pointing triangle cut its outlook for fourth-quarter revenue as the market for drugs that increase insulin levels grew slower than expected, but the company ...

"Eli Lilly Cuts 4Q Sales Outlook After Sluggish Growth for Incretin Drugs," published at 10:06 a.m. ET, incorrectly said the outlook was around $400 below the low end of its last estimated range ...

(RTTNews) - Drug major Eli Lilly and Co. (LLY ... The company also issued fiscal 2025 outlook, expecting a growth. Revenue would be in the range of $58.0 billion to $61.0 billion, a growth ...

TD Cowen analyst Steve Scala reiterated a Buy rating on Eli Lilly & Co (LLY – Research Report) today and set a price target of $900.00.Stay ...

Eli Lilly forecasts $45 billion in 2024 revenue, a 32% growth but $400 million below Q3 guidance. Mounjaro and Zepbound expected to contribute $3.5 billion and $1.9 billion, respectively ...

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50 ...

Eli Lilly shares could remain under the microscope on Wednesday after falling sharply Tuesday as the pharmaceutical giant lowered its 2024 full-year revenue forecast. This tepid outlook adds to ...

Eli Lilly cut its outlook for fourth-quarter revenue as the market for drugs that increase insulin levels grew slower than expected, but the company sees healthy growth in 2025 due to the success ...